The 489% net loss expansion and $5.4M operating expense base on only $597K revenue signal severe cash burn — the $6.0M cash balance likely funds less than 12 months of operations absent further capital raises. Monitor for equity or debt financing announcements, and watch for FDA IND submissions and Q-Submission progress as binary catalysts in 2026.
Price Chart
Executive Summary
YD Bio reported FY2025 net revenue of $597K (+17% YoY) but net loss widened to $8.3M from $1.4M, driven by a $3.2M warrant liability charge and a 236% surge in operating expenses to $5.4M. The company ended the year with $6.0M cash and outlined 2026 milestones including IND submissions for Dry Eye Disease and Age-Related Macular Degeneration, plus an FDA Q-Submission for its pancreatic cancer detection program.
Key Financial Metrics
Key Facts
- FY2025 net revenue $596,817, up 17% from $510,360 in FY2024
- Net loss widened to $8,311,316 from $1,411,559, a 489% increase
- Operating expenses surged 236% to $5.4M, driven by $1.1M in restructuring costs, $1.1M in R&D for licensed patents, and $1.3M in staff costs
- Change in fair value of warrant liabilities was a $3.17M non-cash charge
- Cash and cash equivalents $6.0M as of Dec 31, 2025, up from $3.1M, boosted by $13.9M equity raise
- Gross margin compressed to 28% from 30% due to sales mix shift toward lower-margin pharmaceuticals
- Top product Keytruda injection generated $133K revenue, up from $85K in FY2024
- Company plans IND submissions for Dry Eye Disease and Age-Related Macular Degeneration in 2026
- OkaiDx Pancreatic Cancer Early Detection Program targeting FDA Q-Submission for Breakthrough Device eligibility
- Non-binding MOU to merge with EG BioMed announced Jan 6, 2026
Financial Impact
Net loss of $8.3M on $597K revenue, with cash burn rate implied by $5.3M operating loss; $6.0M cash provides limited runway
Risk Factors
- Cash runway insufficient to fund operations through 2026 without additional capital raises, likely dilutive
- Warrant liability revaluation could continue to create large non-cash earnings volatility
- Clinical and regulatory milestones (IND, Q-Submission) may be delayed or fail, eliminating upside catalysts
- Revenue concentration in low-margin pharmaceutical reselling (Keytruda, Mounjaro) limits gross margin expansion
- Integration risk from pending EG BioMed merger and Safe Save Medical acquisition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285588 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 8w ago | Press Release | $3.78 $7.42 | ▼ −96.56% | ▼ −96.24% | $5.29 (−40.13%) |
Aug 11, 2026 10w ago | 6-K | $2.73 $3.93 | ▲ +43.77% | ▲ +44.83% | $5.29 (+93.77%) |
Apr 30, 2026 25w ago | Press Release | $4.80 $3.07 | ▲ +36.15% | ▲ +41.41% | $5.29 (−10.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers